HUP9902437A2 - Gamma-Hidroxi-vajsavamid-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó, gyógyszerfüggőség kezelésére alkalmas gyógyszerkészítmények - Google Patents

Gamma-Hidroxi-vajsavamid-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó, gyógyszerfüggőség kezelésére alkalmas gyógyszerkészítmények

Info

Publication number
HUP9902437A2
HUP9902437A2 HU9902437A HUP9902437A HUP9902437A2 HU P9902437 A2 HUP9902437 A2 HU P9902437A2 HU 9902437 A HU9902437 A HU 9902437A HU P9902437 A HUP9902437 A HU P9902437A HU P9902437 A2 HUP9902437 A2 HU P9902437A2
Authority
HU
Hungary
Prior art keywords
hydroxybutyric acid
alkyl
acid amides
gamma
contg
Prior art date
Application number
HU9902437A
Other languages
English (en)
Inventor
Roberto Cacciaglia
Lorenza Guano
Antonella Loche
Vincenzo Perlini
Original Assignee
Laboratorio Farmaceutico C.T. S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio Farmaceutico C.T. S.R.L. filed Critical Laboratorio Farmaceutico C.T. S.R.L.
Publication of HUP9902437A2 publication Critical patent/HUP9902437A2/hu
Publication of HUP9902437A3 publication Critical patent/HUP9902437A3/hu
Publication of HU228595B1 publication Critical patent/HU228595B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A találmány tárgya az (I) általánős képletű g-hidrőxi-vajsavamid-származékők alkalmazása kábítószerfüggőség, példáűl herőin-, mőrfin-és pszichőaktív kábítószerfüggőség, tővábbá alkőhőlizműs kezelésérealkalmas gyógyszerkészítmény előállítására. Az (I) általánős képletben R1 jelentése egy vagy több 5 és 7 közötti számú gyűrűatőmőt tartalmazókarbőciklűsős vagy heterőciklűsős arőmás gyűrűt, vagy ezek keverékéttartalmazó mőnő- vagy pőliciklűsős arőmás csőpőrt, ahől a gyűrűk adőttesetben egy vagy több 1-8 szénatőmős alkil-, 1-8 szénatőmős alkőxi-,aminő-, 1-8 szénatőmős mőnő- vagy dialkil-aminő-csőpőrttal vagyhalőgénatőmmal vannak helyettesítve, ahől az 1-8 szénatőmős alkil- ésaz 1-8 szénatőmős alkőxicsőpőrt egy vagy több kettős vagy hármaskötést tartalmazhat vagy egy vagy több halőgénatőmőt tartalmazócsőpőrttal lehet helyettesítve; R2 jelentése egyenes vagy elágazó láncú alkilcsőpőrt, egy vagy többkettős, vagy hármas kötést tartalmazó vagy egy, vagy több arőmáscsőpőrttal helyettesített alkilcsőpőrt; Q jelentése hidrőgénatőm vagy 1-6 szénatőmős egyenes vagy elágazóláncú alkilcsőpőrt; n értéke 1 és 4 közötti egész szám; T1 és T2 jelentése egymástól függetlenül hidrőgénatőm vagy 1-6szénatőmős egyenes vagy elágazó láncú alkilcsőpőrt. A fentivegyületekkel csökkenthető a krónikűs alkőhőlisták alkőhőltartalmúitalők főgyasztása iránti vágya, és kezelhető az alkőhől- absztinenciaszindróma. A találmány kiterjed a fenti vegyületek előállítására,tővábbá az ezeket tartalmazó készítményekre is. ŕ
HU9902437A 1996-08-09 1997-08-07 Gamma-hydroxybutyric acid amides, process to prepare them, use gamma-hydroxybutyric acid amides, and pharmaceuticals contg. them for the treatmant of drug abusing HU228595B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96MI001732A IT1283782B1 (it) 1996-08-09 1996-08-09 Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
PCT/EP1997/004309 WO1998006690A1 (en) 1996-08-09 1997-08-07 USE OF η-HYDROXYBUTYRIC ACID AMIDES IN THE TREATMENT OF DRUG ADDICTION AND IN PARTICULAR OF ALCOHOLISM

Publications (3)

Publication Number Publication Date
HUP9902437A2 true HUP9902437A2 (hu) 1999-12-28
HUP9902437A3 HUP9902437A3 (en) 2001-07-30
HU228595B1 HU228595B1 (en) 2013-04-29

Family

ID=11374795

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902437A HU228595B1 (en) 1996-08-09 1997-08-07 Gamma-hydroxybutyric acid amides, process to prepare them, use gamma-hydroxybutyric acid amides, and pharmaceuticals contg. them for the treatmant of drug abusing

Country Status (13)

Country Link
US (2) US6436998B1 (hu)
EP (1) EP0932597B1 (hu)
JP (1) JP4259615B2 (hu)
AT (1) ATE215065T1 (hu)
AU (1) AU4379097A (hu)
CA (1) CA2263328C (hu)
DE (1) DE69711411T2 (hu)
DK (1) DK0932597T3 (hu)
ES (1) ES2174287T3 (hu)
HU (1) HU228595B1 (hu)
IT (1) IT1283782B1 (hu)
PT (1) PT932597E (hu)
WO (1) WO1998006690A1 (hu)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491747B2 (en) 2001-07-30 2009-02-17 Merck Patent Gmbh Butyric acid derivatives

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193777T3 (es) 1998-12-23 2003-11-01 Orphan Medical Inc Disoluciones estables e inalterables microbiologicamente de sal de gamma-hidroxibutirato para el tratamiento de la narcolepsia.
AU2003295393A1 (en) * 2002-11-01 2004-06-07 Baylor Research Institute Ghb treatment methods
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
EP2062875A1 (en) * 2007-11-13 2009-05-27 LABORATORIO FARMACEUTICO C.T. S.r.l. New polymorphic forms of n-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
MX2020011961A (es) 2010-03-24 2022-04-19 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
ITMI20132041A1 (it) * 2013-12-06 2015-06-07 Ct Lab Farm Srl Derivati dell'acido gamma-idrossibutirrico, loro preparazione e loro uso medico.
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
ITUB20152860A1 (it) 2015-08-04 2017-02-04 Laboratorio Farm C T S R L Selezionata amide dell?acido ?-idrossibutirrico e suoi usi nel trattamento dell?abuso da alcool
ITUA20164040A1 (it) * 2016-06-01 2017-12-01 Laboratorio Farm C T S R L Procedimento per la preparazione di polimorfo a
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CN113395960A (zh) 2018-11-19 2021-09-14 爵士制药爱尔兰有限公司 抗酒精药物制剂
JP2022522270A (ja) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物
WO2023126076A1 (en) 2022-01-03 2023-07-06 Laboratorio Farmaceutico C.T. S.R.L. Medical use of an amide of y-hydroxybutyric acid in the treatment of fragile x syndrome
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940258A (en) * 1971-11-26 1976-02-24 Gaf Corporation Method for controlling aquatic weeds with N-phenylalkyl-γ-hydroxybutyramide
JPS6016432B2 (ja) * 1977-07-26 1985-04-25 グレラン製薬株式会社 複素環式化合物類およびその製造法
DE3855875T2 (de) * 1987-02-23 1997-08-28 Ono Pharmaceutical Co Thiazolidin-Derivate
IT1217783B (it) * 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1248588B (it) * 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
EP0763016B1 (en) * 1994-06-01 2000-01-26 Axys Pharmaceuticals, Inc. Compositions and methods for treating mast-cell mediated conditions
NO307879B1 (no) * 1995-09-18 2000-06-13 Sankyo Co Nye ureaderivater med ACAT-inhiberende aktivitet og farmasøytisk preparat inneholdende disse
ES2237850T3 (es) * 1997-10-14 2005-08-01 Mitsubishi Pharma Corporation Compuestos de piperazina y su uso medicinal.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491747B2 (en) 2001-07-30 2009-02-17 Merck Patent Gmbh Butyric acid derivatives

Also Published As

Publication number Publication date
DE69711411T2 (de) 2002-11-07
ES2174287T3 (es) 2002-11-01
US6436998B1 (en) 2002-08-20
US20020165224A1 (en) 2002-11-07
JP4259615B2 (ja) 2009-04-30
PT932597E (pt) 2002-09-30
EP0932597A1 (en) 1999-08-04
DK0932597T3 (da) 2002-06-24
AU4379097A (en) 1998-03-06
IT1283782B1 (it) 1998-04-30
HU228595B1 (en) 2013-04-29
EP0932597B1 (en) 2002-03-27
US6770784B2 (en) 2004-08-03
CA2263328C (en) 2006-07-25
WO1998006690A1 (en) 1998-02-19
JP2000516225A (ja) 2000-12-05
ITMI961732A1 (it) 1998-02-09
CA2263328A1 (en) 1998-02-19
HUP9902437A3 (en) 2001-07-30
ITMI961732A0 (hu) 1996-08-09
ATE215065T1 (de) 2002-04-15
DE69711411D1 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
HUP9902437A2 (hu) Gamma-Hidroxi-vajsavamid-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó, gyógyszerfüggőség kezelésére alkalmas gyógyszerkészítmények
ES8506021A1 (es) Procedimiento para preparar derivados de 4-oxo-1, 4-dihidroquinoleina
MY100343A (en) Amide derivative and external medicament comprising same
YU211087A (en) Process for obtaining new n-substituted benzimidazolic derivatives
HUP0001741A2 (hu) Antibakteriális hatású aza-biciklo-karbamoil-oxi-mutilin-származékok, eljárás ezek előállítására, ezeket tartalmazó készítmények és alkalmazásuk
TW365604B (en) Anthracyclinone derivatives
NZ334981A (en) Anti-convulsant derivatives such as topiramate for treating neuropathic pain
HUT41025A (en) Process for preparing octahydro-indolizine derivatives and pharmaceutical compositions containing such compounds as active ingredients
NZ219052A (en) Octahydroindolizine derivatives and pharmaceutical compositions
BG101671A (en) Diclavunic salt with diaminoether and method for its preparation
HUT71512A (en) N-(3-chlorophenyl)-piperazine derivatives for producing alkyl-trazodon derivatives and process for producing them
IL107242A0 (en) Derivatives of benzeneborinic acid, preparation thereof and use thereof as synthetic intermediates
NZ333587A (en) Topiramate derivatives useful in treating psoriasis
GR3033109T3 (en) Reaction products of anilines and bisphenolgylcidylethers, a process for their preparation and their use as hardening accelerators
PL324884A1 (en) Application of prostane derivatives and their compositions with antibiotics in treating bacterial infections
ES8303297A1 (es) Un procedimiento para la preparacion de un nuevo reptido activo.
GB1431617A (en) Benzopyrano- and benzothiopyranoindazole n-oxides
GB1410319A (en) 6-aza-3h-1,4-benzodiazepines
SU1067801A1 (ru) 5-(n-НИТРО-β-ОКСИФЕНЕТИЛ)-1-МЕТИЛ-4,5,6,7-ТЕТРАГИДРОИМИДАЗО(4,5-С)ПИРИДИНДИГИДРОХЛОРИД, ОБЛАДАЮЩИЙ АНАЛЬГЕТИЧЕСКОЙ И ПРОТИВОВОСПАЛИТЕЛЬНОЙ АКТИВНОСТЬЮ
MX9703869A (es) Benzamida enterocinetica.